Brief: Cantargia Presents Positive Results For Nadunolimab At Aacr 2023

Cantargia AB

14/03/2023 20:34

March 14 (Reuters) - Cantargia AB  CANTA.ST :
    * CANTARGIA PRESENTS POSITIVE RESULTS FOR NADUNOLIMAB AT
AACR 2023
INCLUDING NEW CLINICAL DATA IN PANCREATIC CANCER
    * CANTARGIA - KEY FINDING IS THAT PANCREATIC CANCER 
PATIENTS WITH
HIGH TUMOR LEVELS OF IL1RAP, BENEFIT MOST FROM NADUNOLIMAB
COMBINED WITH CHEMOTHERAPY

Source text for Eikon:  ID:nWkr8vs2Mg 
Further company coverage:  CANTA.ST 

 ((Reuters.Briefs@thomsonreuters.com;))